ANN ARBOR, Mich., – Sept 18, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has selected Mr. Anurag Gupta for its expanded Board of Directors.  Among the many significant accomplishments during his career, Mr. Gupta has served as: the CEO of Global Data Services for TBG, the President for Europe, Middle East, and Africa region for BrightPoint, Inc, and the Executive Vice President of the CMS Division at IHS Markit.  Mr. Gupta currently serves as an Independent Director on the boards of Roseburg Forest Products Co. and Drive My Way, Inc.

“We are pleased to welcome Anurag as the first, of several, new independent directors to be joining the Kraig Lab’s board,” said chairman and CEO, Kim Thompson.  “Anurag’s background and experience in corporate management, technology development, international operations, and investor relations will be an asset to the Company as we continue to grow.”

The addition of Mr. Gupta to the board will expand the overall skillset, perspective and experience necessary, to support and drive growth for all of the Company’s stakeholders. 

Mr Gupta’s term will begin during the fourth quarter and he will serve on the audit committee and compensation committees for the duration of his time as a director.

“I am excited about joining the Board of Kraig Labs and look forward to working alongside our Founder and CEO, Kim Thompson and my fellow Board members,” said Mr. Gupta.  “It is exciting to be a part of an innovative biotechnology company that is doing amazing work towards the development and commercialization of Spider Silk technology.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Sept 13, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its CEO, Kim Thompson, was recently recognized as one of MyTechMag magazine’s top 20 pioneering CEO’s of 2019.  In the recent CEO edition, Mr Thompson shares the incredible story of the founding of Kraig Labs, as well as how his outsider status and determination delivered success against overwhelming odds. 

In selecting the top 20 pioneering CEO’s of 2019, MyTechMag selection criteria included a review of the complexity of the challenges overcome, the growth of the underlying business, and the CEO’s ability to harness their team’s potential.

“I am honored to have been selected for this recognition.  MyTechMag’s award comes on the verge of a very exciting time for Kraig Labs, as we expect to soon be formally launching commercial scale production of our eco-friendly recombinant spider silk,” said CEO and Founder, Thompson.  “Kraig Labs has been pioneering the way forward for cost effective spider silk production and today’s recognition of my work and our Company’s role in bringing this innovation to market is an honor.  Together, our team has faced and conquered numerous obstacles that stood between us and our goal.  In that spirit I accept this award as recognition for the entire Kraig Labs team, including our valued employees and shareholders.”

You can find a copy of the article at Kraiglabs.com or read the full magazine article at MyTechMag.com or read Mr Thompson’s profile

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – Sept 12, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has narrowed its list of candidates to seven highly qualified individuals to fill the four additional Board of Directors member positions that the Company plans to appoint as part of its preparations for a potential uplist to a national exchange. The Company has received nearly 200 qualified applications for the new board positions. Senior management, after completing vigorous selection process, has narrowed the field down to seven finalists.  These candidates offer a broad and diverse background, ranging from finance and compliance to global operations, marketing, and tech development.  This diversity in experience was intentionally curated, by management, to seat a board able to bring wide ranging knowledge and oversight.

The Company is entering its final selection round and anticipates making a determination, and announcing the appointments, of the new board members, within the next three weeks.

“I am very excited about each of our finalists; I know that those who are ultimately selected will strengthen our Company.  I would like to thank all of the applicants who took the time to go through the selection process,” said Board Chairman and CEO Kim Thompson.

As discussed and approved, by the Company’s shareholders, during the annual shareholder meeting held in July, the appointment of these new board members is part of the Company efforts to position the company for a potential uplist and to strengthen corporate management and oversight as we prepare for production ramp up.

The Company will issue an announcement of the new board members when the selection process in finalized.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

The following is correspondence between the CEO and two of our shareholders which we believe is informative on the Company’s perspective on ballot initiatives for the upcoming shareholder meeting.

Gary,

Thank you for your input and support.

I just responded to another shareholder’s inquiry and am including my response to him below, as some of his concerns overlap yours and I think are representative of questions and input I have received from a few others.

On the question of the preferred stock, I think your concerns have some merit.  Super majorities do have a mixed history.  My intention when I received the preferred back in 2013 was to make sure that we always had the votes necessary to execute on our business plan.  The thinking at that time was that if there was an opportunity for a significant acquisition, merger or up-list, time would be of the essence.  The corporate charter was amended at that time to allow a majority to take such action without a shareholder meeting.  The reason was that it takes significant planing, delays and expense to hold a shareholder meeting and a significant opportunity could slip through our hands in that time.

It is a bit ironic then that, now, when we have a possible opportunity for an up-list, we are never the less holding a meeting of shareholders.  

My small team is fully taxed preparing for the meeting while keeping everything else afloat and executing on our plans for Vietnam.  It is fair to say that I am over-taxed as well.  I will keep an open mind about the super majority and seek input from the team and our securities counsel in the coming weeks and months.

Kim

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.

---

Zach,

Thank you for your email.  I am responding to you directly because it looks like you have done your homework on the history of RS.

I do not doubt the Stern data.  Typically when a company does a RS it is because the stock price has been eroding over time and the company can not maintain its exchange listing at the new stock price.  While I have not seen any data, it may also be the case that companies enter into a RS because of covenants on their debt interments or under presser from debt holders. Of course such companies have a tendency to under perform.  They have a history of under-performance.

For Kraig Labs, that is simply not the case.  Our stock has shown significant historical gains (even accounting for the recent pull back) and we are hitting the major milestones we have set for ourselves in terms of setting up production and early stage commercialization.  It is that growth which has given us a possible path to a national exchange.

Historically, we have run this Company on very thin financing.  Now that we need to ramp up production, thin financing will not allow us to ramp up quickly enough to meet our targets or to satisfy the potential customers that we are talking with.

I can not predict the stock price.  I do not know where it is going any more than anyone else.  But I do have strong opinions about what it will take to make the Company a success and what it will take to bring our products to market in a manner that will allow us to beat the competition and capture market share.  My philosophy has always been to focus on the Company’s fundamentals and executing on our business plan.  I do believe that focusing on growing the Company will ultimately benefit our shareholders.

My suggestion would be, that the Stern School data is not as relevant as another set of data.  What happens, statistically, to share price and long term shareholder value when an OTC Company up-lists? 

Our immediate plan to to shoot for the up-list.  There is no guarantee that we will make the up-list.  As I see it we have a relatively small window in which to do this and several moving pieces which need to all move through the window at the same time.  To be frank, my stress levels in engineering and managing this process are very high.  Surprisingly, this is because I think we might just achieve this success and hit the remaining marks in our business plan over the near and medium term.  Some times success itself can be a stresser.  I think the market feels it too.

I know the recent drop in share price is also stressing you and others.  I am personalty affected as well.  But I see opportunity and the possibility of growing this small boat into a bigger and stronger ship.  I chose growth. While I am stressed, I am also excited and, I must confess, elated.

Thank you for your support and your input.  If you chose not to take this ride and see these opportunities through with us I understand.  There are risks, which I do not want to minimize.  It is no my role, as I see it, to convince people to buy the stock or to maintain their investment.  My role it to grow the Company and put in place a strategic vision for market dominance. 

One of the most frustrating aspects of my work is the added burden of being a penny stock and OTC company.  In essence, companies that have made the jump to a national exchange have received at some level a review and participation by investment banks and their client institutions.  Companies which have not gone through that process are always suspect from the perspective of Wall Street and other constituents.  That translates directly to higher costs and closed doors.  If the Company is going to show exponential growth, which is an essential part of our business plan, we need to kick open those doors.  

We are arming ourselves with a battering ram.  I intend to knock on those doors till the hinges come off and the path for our growth is wide open.

Good luck and good fortune to you and for all of us.  

Kim

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.

Increased transgenic egg production and staffing of new operations among its New Vietnamese Subsidiary’s next steps

ANN ARBOR, Mich., – May 14, 2018 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers provides an update on progress towards the commercialization of spider silk technology following last week’s announcement of the formation of its Vietnamese subsidiary, Prodigy Textiles Co,. Ltd (“Prodigy”).  The Company views Prodigy as its main production arm for spider silk technologies.

The Company is gearing up production of its proprietary spider silk silkworm eggs in preparation for shipment to Prodigy.  These Silkworms are slated to be the first transgenics produced at Prodigy.

Kraig Labs has identified a facility, in Quang Nam province, with the capacity to support operations and is working with local experts to update and buildout the facility to meet production specifications.    

To bring Prodigy production operations online, Kraig Labs has accelerated Prodigy’s staffing and hiring plans.  Key technical and administration positions within Prodigy have been identified and the Company is working with its consultants in Vietnam to fill these positions. 

Company management is now preparing to travel to Vietnam to oversee Prodigy’s launch, where they will also be oversee hiring core staff, the transfer of the Company’s spider silk silkworm technology, and the beginning of operations. 

“Momentum at Prodigy is growing and we’re focused on the exciting milestones ahead,” said Jon Rice, COO.  “We are busy preparing silkworm eggs for shipment and putting the team in place at Prodigy to hit the ground running.  We are now taking concrete steps to build on all the work we’ve done in Vietnam and to convert that into a thriving operation for spider silk production.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

Dear Shareholders,

There have been a number of request for a supplement to the last issue of spider sense regarding our progress towards obtaining an enterprise registration certificate, or equivalent in Vietnam.  The Enterprise Registration Certificate (ERC) is effectively our business license to conduct our operations in Vietnam. 

It’s an important subject, as Vietnam is one of the countries with the existing infrastructure to support mass production of our spider silk.  Existing silkworm infrastructure should translate into superior quality and great cost reductions, compared to building out from scratch at shareholder expense.  For these reasons we view our discussions with officials in silk producing countries, including those in Vietnam, as being critical for our commercialization efforts. 

That being said, negotiations with high level government offices are often challenging, with multiple competing interests vying for influence.  These challenges exist in any bureaucracy.   Over the last twelve months, the Company, and its consultants in Vietnam, held a series of successful meetings with top officials within central government and provincial offices.   Each of these meetings moved our project forward.  This forward progress was not without contention from some individuals within the bureaucracy.   That, as you can appreciate, is how governmental systems work. These meetings have brought us closer to our goal.

We have assembled the right team of people in Vietnam working within the provinces and at the central government level to see this process to successfully completion.  In parallel with working to secure our ERC, or equivalent authorization, we are working with provincial officials and our consultants in Vietnam to identify local staff and facilities.   

Recent questions surrounding news stories, translated from the original Vietnamese sources, highlight the challenges of working across languages and with large government agencies.  Different offices within the bureaucracy have different priorities and this leads to the contentious nature of some of these meetings. 

Those article have described some of the more touchy elements of those meetings, while excluding key portions and conclusions.  The Company has made significant progress over the last six months.  We believe that we are on track for international production and that the process in Vietnam in particular is coming to ahead.      

While operations in a major silk producing country remain a key element of the Company’s growth plan, it is not our only approach.  In 2017, we made two major moves to expand our domestic operations.  In the first quarter, we leased 15 acres of land in Texas and planted our first 2,000 mulberry trees.  In the fourth quarter, we opened a new production and research headquarters in Michigan, more than tripling our floor plan and capacity.  Combined, these two domestic facilities represent a significant increase in our domestic capacity. 

Our approach to developing and producing spider silk leverages nature’s silk factory, the silkworm.  This approach is driven by; molecular biology, process simplicity, cost benefits, and competitive advantage.   The infrastructure, tools, and skills, to produce high quality silk, already exist.  We are certain that our cost effective approach, combined with leveraging existing infrastructure, are key to seeing this market grow into the thriving disruptive technology it has the potential to become. 

We do believe that we have the greatest and most enthusiastic group of shareholders that any company could ask for and we thank all of you for your continued support and even for your occasional criticism.  You are appreciated.

Thank you. 

Kim Thompson                                  Jon Rice
CEO                                                        COO

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could”, “spectacular”, “dramatic”, or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This letter does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

 

 

ANN ARBOR, Mich., -May 19, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has delivered the first samples of Dragon Silk to the US Army for independent testing.  The Company provided several samples of individual silk filaments as well as finished Dragon Silk thread for evaluation.

“We are pleased to report that we have delivered the first samples of Dragon Silk to our US Army sponsor for independent performance confirmation,” said the Company’s COO Jon Rice.  “These samples mark the starting point for what we hope will be a long lasting and profound impact on protective equipment for those dedicated to protecting us.  The speed that our Indiana facility was able to ramp up to meet this request helps to confirm, that we have the ability to promptly deliver a top quality, cost effective, fiber to the Army and future commercial customers.”

The Company is producing Dragon Silk at its Indiana factory and expects to make final delivery of the shoot packs for ballistic testing later this year.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter.

For more information about Spider Silk, check it out at www.kraiglabs.com/spider-silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., -December 19, 2016- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it completed the first batch of Dragon Silk™ cocoon production for its recently reported military contract.  The fibers will soon be headed to a reeling facility to be prepared for delivery to Warwick Mills.

The Company will contract Warwick Mills to produce ballistic shoot packs, for delivery to the US Army, based on the Company’s Dragon Silk technology.  The Company expected to make final delivery to the US Army in the second quarter of 2017.

“The Indiana factory scale up of our proprietary recombinant spider silk, we call Dragon silk, has exceeded our expectations.  As we ship this first batch of Dragon Silk cocoons dedicated for the US Army, we are already beginning to prepare for production of fibers ready for commercial sale to some of our primary end users,” said Company Founder and CEO Kim Thompson. 

The Company will now begin to sell its Dragon Silk and Monster Silk fibers, in earnest, to the various parties that have submitted sample requests, with priority given to substantive collaborative development agreements and key end uses.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter.

For more information about Spider Silk, check it out at www.kraiglabs.com/spider-silk.

About Warwick Mills

For the past century, Warwick Mills has been a leader in the engineering of technical textiles for protective applications. Warwick develops and integrates complex fiber composites for the most challenging safety applications. Its cooperative development strategy relies on its core technologies in technical textiles, custom adhesives, and performance coatings, from research and development to testing and full-scale manufacturing. This strategy ensures customer confidence for every challenge.

http://www.warwickmills.com

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

CEO and COO to discuss spider silk commercialization and corporate developments

ANN ARBOR, Mich., – November 30, 2015 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announces a conference call to be hosted by Kim Thompson and Jon Rice on Friday, December 4, 2015 at 4:30 PM EST. The Company invites all shareholders and other interested parties to participate in the call.

Thompson, the Company’s CEO and Founder and Rice, the Company’s COO, will update shareholders on production, scientific milestones, commercialization strategy and corporate developments.  Following the Company progress update, Thompson and Rice will hold a questions and answer session moderated by Ben Hansel.  Shareholders are invited to submit question to IR@kraiglabs.com in advance of the call.

Interested parties are invited to dial the toll free number below.

1-866-906-9888 and when prompted, enter access code 9285926 followed by the # (pound) sign.

It is recommended that callers dial in approximately five minutes before the conference is scheduled to begin.

The Company anticipates posting a recording of the conference call on the Company website shortly after the call for interested parties who are unable to attend the call.

Conference call: 4:30 p.m. EST (Eastern Standard Time), Friday, December 4, 2015.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC.

(720) 288-8495

ir@KraigLabs.com